{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:44:01Z","timestamp":1791420241382,"version":"4.3.3"},"reference-count":59,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":193,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["NE 832\/4-1 and HE 3186\/11-1"],"award-info":[{"award-number":["NE 832\/4-1 and HE 3186\/11-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Cancer"],"published-print":{"date-parts":[[2015,8,15]]},"DOI":"10.1002\/ijc.29442","type":"journal-article","created":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T09:08:16Z","timestamp":1421831296000},"page":"978-990","source":"Crossref","is-referenced-by-count":49,"title":["Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells"],"prefix":"10.1002","volume":"137","author":[{"given":"Katharina","family":"Hammer","sequence":"first","affiliation":[{"name":"Oncolytic Adenovirus Group; German Cancer Research Center (DKFZ); Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kazcorowski","sequence":"additional","affiliation":[{"name":"Molecular OncoSurgery; German Cancer Research Center (DKFZ) and Department of General; Visceral and Transplantation Surgery; University of Heidelberg; Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Molecular OncoSurgery; German Cancer Research Center (DKFZ) and Department of General; Visceral and Transplantation Surgery; University of Heidelberg; Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Behr","sequence":"additional","affiliation":[{"name":"Oncolytic Adenovirus Group; German Cancer Research Center (DKFZ); Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schemmer","sequence":"additional","affiliation":[{"name":"Department of General; Visceral and Transplantation Surgery; University of Heidelberg; Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Herr","sequence":"additional","affiliation":[{"name":"Molecular OncoSurgery; German Cancer Research Center (DKFZ) and Department of General; Visceral and Transplantation Surgery; University of Heidelberg; Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk M.","family":"Nettelbeck","sequence":"additional","affiliation":[{"name":"Oncolytic Adenovirus Group; German Cancer Research Center (DKFZ); Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,20]]},"reference":[{"key":"10.1002\/ijc.29442-BIB0001|ijc29442-cit-0001","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1002\/ijc.29442-BIB0002|ijc29442-cit-0002","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrmicro1927","article-title":"Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded","volume":"6","author":"Cattaneo","year":"2008","journal-title":"Nat Rev Microbiol"},{"key":"10.1002\/ijc.29442-BIB0003|ijc29442-cit-0003","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/mt.2009.266","article-title":"Current issues and future directions of oncolytic adenoviruses","volume":"18","author":"Yamamoto","year":"2010","journal-title":"Mol Ther"},{"key":"10.1002\/ijc.29442-BIB0004|ijc29442-cit-0004","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/mt.2009.194","article-title":"Cell carriers for oncolytic viruses: Fed Ex for cancer therapy","volume":"17","author":"Willmon","year":"2009","journal-title":"Mol Ther"},{"key":"10.1002\/ijc.29442-BIB0005|ijc29442-cit-0005","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/sj.mt.6300128","article-title":"Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy","volume":"15","author":"Hamada","year":"2007","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1002\/ijc.29442-BIB0006|ijc29442-cit-0006","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/stem.645","article-title":"Concise review: mesenchymal stem cell tumor-homing: detection methods in disease model systems","volume":"29","author":"Reagan","year":"2011","journal-title":"Stem Cells"},{"key":"10.1002\/ijc.29442-BIB0007|ijc29442-cit-0007","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2004-04-1559","article-title":"Human mesenchymal stem cells modulate allogeneic immune cell responses","volume":"105","author":"Aggarwal","year":"2005","journal-title":"Blood"},{"key":"10.1002\/ijc.29442-BIB0008|ijc29442-cit-0008","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1089\/hum.2010.135","article-title":"Mesenchymal stem cells and cancer: tumor-specific delivery vehicles or therapeutic targets?","volume":"21","author":"Dwyer","year":"2010","journal-title":"Hum Gene Ther"},{"key":"10.1002\/ijc.29442-BIB0009|ijc29442-cit-0009","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1634\/stemcells.21-4-389","article-title":"Approaches to utilize mesenchymal progenitor cells as cellular vehicles","volume":"21","author":"Pereboeva","year":"2003","journal-title":"Stem Cells"},{"key":"10.1002\/ijc.29442-BIB0010|ijc29442-cit-0010","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1634\/stemcells.2007-0758","article-title":"Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma","volume":"26","author":"Sonabend","year":"2008","journal-title":"Stem Cells"},{"key":"10.1002\/ijc.29442-BIB0011|ijc29442-cit-0011","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10549-006-9449-8","article-title":"Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma","volume":"105","author":"Stoff-Khalili","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1002\/ijc.29442-BIB0012|ijc29442-cit-0012","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1158\/1535-7163.MCT-05-0334","article-title":"Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses","volume":"5","author":"Komarova","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1002\/ijc.29442-BIB0013|ijc29442-cit-0013","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1476-4598-10-134","article-title":"Mesenchymal stem cells as carriers and amplifiers in CRAd delivery to tumors","volume":"10","author":"Xia","year":"2011","journal-title":"Mol Cancer"},{"key":"10.1002\/ijc.29442-BIB0014|ijc29442-cit-0014","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/cgt.2009.67","article-title":"Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells","volume":"17","author":"Dembinski","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"10.1002\/ijc.29442-BIB0015|ijc29442-cit-0015","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1158\/1078-0432.CCR-09-1292","article-title":"Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model","volume":"15","author":"Mader","year":"2009","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1002\/ijc.29442-BIB0016|ijc29442-cit-0016","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/cgt.2010.4","article-title":"Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study","volume":"17","author":"Garcia-Castro","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"10.1002\/ijc.29442-BIB0017|ijc29442-cit-0017","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0301-472X(00)00134-X","article-title":"Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells","volume":"28","author":"Conget","year":"2000","journal-title":"Exp Hematol"},{"key":"10.1002\/ijc.29442-BIB0018|ijc29442-cit-0018","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1089\/hum.2007.034","article-title":"Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors","volume":"18","author":"Hakkarainen","year":"2007","journal-title":"Hum Gene Ther"},{"key":"10.1002\/ijc.29442-BIB0019|ijc29442-cit-0019","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.bbrc.2005.05.055","article-title":"Fiber-modified adenovirus vectors mediate efficient gene transfer into undifferentiated and adipogenic-differentiated human mesenchymal stem cells","volume":"332","author":"Mizuguchi","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1002\/ijc.29442-BIB0020|ijc29442-cit-0020","doi-asserted-by":"crossref","first-page":"9706","DOI":"10.1128\/JVI.72.12.9706-9713.1998","article-title":"An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism","volume":"72","author":"Dmitriev","year":"1998","journal-title":"J Virol"},{"key":"10.1002\/ijc.29442-BIB0021|ijc29442-cit-0021","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1128\/JVI.70.10.6839-6846.1996","article-title":"Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism","volume":"70","author":"Krasnykh","year":"1996","journal-title":"J Virol"},{"key":"10.1002\/ijc.29442-BIB0022|ijc29442-cit-0022","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-09-3167","article-title":"Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors","volume":"16","author":"Nokisalmi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1002\/ijc.29442-BIB0023|ijc29442-cit-0023","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-11-2852","article-title":"A phase I clinical trial of Ad5.SSTR\/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer","volume":"18","author":"Kim","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1002\/ijc.29442-BIB0024|ijc29442-cit-0024","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol Ther"},{"key":"10.1002\/ijc.29442-BIB0025|ijc29442-cit-0025","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/cgt.2009.3","article-title":"Armed replicating adenoviruses for cancer virotherapy","volume":"16","author":"Cody","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"10.1002\/ijc.29442-BIB0026|ijc29442-cit-0026","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.virol.2009.09.030","article-title":"Transgene expression by oncolytic adenoviruses is modulated by E1B19K deletion in a cell type-dependent manner","volume":"395","author":"Rohmer","year":"2009","journal-title":"Virology"},{"key":"10.1002\/ijc.29442-BIB0027|ijc29442-cit-0027","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/gt.2011.141","article-title":"The oncolytic adenovirus AdDeltaDelta enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models","volume":"18","author":"Cherubini","year":"2011","journal-title":"Gene Ther"},{"key":"10.1002\/ijc.29442-BIB0028|ijc29442-cit-0028","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1078-0432.CCR-09-1960","article-title":"Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers","volume":"16","author":"Oberg","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1002\/ijc.29442-BIB0029|ijc29442-cit-0029","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.molmed.2013.08.007","article-title":"TRAIL on trial: preclinical advances in cancer therapy","volume":"19","author":"Stuckey","year":"2013","journal-title":"Trends Mol Med"},{"key":"10.1002\/ijc.29442-BIB0030|ijc29442-cit-0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J Clin Investig"},{"key":"10.1002\/ijc.29442-BIB0031|ijc29442-cit-0031","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat Med"},{"key":"10.1002\/ijc.29442-BIB0032|ijc29442-cit-0032","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/156652309787354612","article-title":"TRAIL gene therapy: from preclinical development to clinical application","volume":"9","author":"Griffith","year":"2009","journal-title":"Curr Gene Ther"},{"key":"10.1002\/ijc.29442-BIB0033|ijc29442-cit-0033","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood-2009-08-239632","article-title":"Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature","volume":"115","author":"Lavazza","year":"2010","journal-title":"Blood"},{"key":"10.1002\/ijc.29442-BIB0034|ijc29442-cit-0034","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ymthe.2003.12.008","article-title":". A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases","volume":"9","author":"Sova","year":"2004","journal-title":"Mol Ther"},{"key":"10.1002\/ijc.29442-BIB0035|ijc29442-cit-0035","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1158\/1078-0432.CCR-03-0512","article-title":"Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter","volume":"10","author":"Jacob","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1002\/ijc.29442-BIB0036|ijc29442-cit-0036","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1245\/ASO.2003.01.021","article-title":"Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter","volume":"10","author":"Katz","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"10.1002\/ijc.29442-BIB0037|ijc29442-cit-0037","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/cgt.2012.46","article-title":"TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells","volume":"19","author":"Moniri","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"10.1002\/ijc.29442-BIB0038|ijc29442-cit-0038","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/cgt.2010.68","article-title":"TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo","volume":"18","author":"Mueller","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"10.1002\/ijc.29442-BIB0039|ijc29442-cit-0039","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/hum.2010.100","article-title":"Selectivity and efficiency of late transgene expression by transcriptionally targeted oncolytic adenoviruses are dependent on the transgene insertion strategy","volume":"22","author":"Quirin","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.1002\/ijc.29442-BIB0040|ijc29442-cit-0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.cgt.7700874","article-title":"Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity","volume":"13","author":"Kaliberov","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"10.1002\/ijc.29442-BIB0041|ijc29442-cit-0041","first-page":"14","article-title":"Usefulness of repeated direct intratumoral gene transfer using hemagglutinating virus of Japan-liposome method for cytosine deaminase suicide gene therapy","volume":"61","author":"Kanyama","year":"2001","journal-title":"Cancer Res"},{"key":"10.1002\/ijc.29442-BIB0042|ijc29442-cit-0042","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.gassur.2003.10.008","article-title":"Specific gene expression and therapy for pancreatic cancer using the cytosine deaminase gene directed by the rat insulin promoter","volume":"8","author":"Wang","year":"2004","journal-title":"J Gastrointestinal Surg Off J Soc Surg Aliment Tract"},{"key":"10.1002\/ijc.29442-BIB0043|ijc29442-cit-0043","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jss.2011.04.021","article-title":"Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method","volume":"172","author":"Ruckert","year":"2012","journal-title":"J Surg Res"},{"key":"10.1002\/ijc.29442-BIB0044|ijc29442-cit-0044","doi-asserted-by":"crossref","first-page":"e48503","DOI":"10.1371\/journal.pone.0048503","article-title":"Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model system","volume":"7","author":"Fredebohm","year":"2012","journal-title":"PloS One"},{"key":"10.1002\/ijc.29442-BIB0045|ijc29442-cit-0045","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.yexcr.2008.11.013","article-title":"Suitability of human mesenchymal stem cells for gene therapy depends on the expansion medium","volume":"315","author":"Apel","year":"2009","journal-title":"Exp Cell Res"},{"key":"10.1002\/ijc.29442-BIB0046|ijc29442-cit-0046","first-page":"3813","article-title":"In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase\/uracil phosphoribosyltransferase fusion gene","volume":"60","author":"Erbs","year":"2000","journal-title":"Cancer Res"},{"key":"10.1002\/ijc.29442-BIB0047|ijc29442-cit-0047","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1741-7015-11-146","article-title":"Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells","volume":"11","author":"Siegel","year":"2013","journal-title":"BMC Med"},{"key":"10.1002\/ijc.29442-BIB0048|ijc29442-cit-0048","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jconrel.2012.04.045","article-title":"Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy","volume":"164","author":"Mehta","year":"2012","journal-title":"J Controlled Release"},{"key":"10.1002\/ijc.29442-BIB0049|ijc29442-cit-0049","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/10430340050015851","article-title":"Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector","volume":"11","author":"Sauthoff","year":"2000","journal-title":"Hum Gene Ther"},{"key":"10.1002\/ijc.29442-BIB0050|ijc29442-cit-0050","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1128\/JVI.65.6.2968-2978.1991","article-title":"Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins","volume":"65","author":"White","year":"1991","journal-title":"J Virol"},{"key":"10.1002\/ijc.29442-BIB0051|ijc29442-cit-0051","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1158\/1078-0432.CCR-06-0244","article-title":"Eliminating established tumor in nu\/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus","volume":"12","author":"Dong","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1002\/ijc.29442-BIB0052|ijc29442-cit-0052","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/cgt.2009.62","article-title":"Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL","volume":"17","author":"Jimenez","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"10.1002\/ijc.29442-BIB0053|ijc29442-cit-0053","doi-asserted-by":"crossref","first-page":"8932","DOI":"10.1158\/0008-5472.CAN-08-3873","article-title":"Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas","volume":"69","author":"Yong","year":"2009","journal-title":"Cancer Res"},{"key":"10.1002\/ijc.29442-BIB0054|ijc29442-cit-0054","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/sj.gt.3302739","article-title":"Melanoma cultures show different susceptibility towards E1A-, E1B-19 kDa- and fiber-modified replication-competent adenoviruses","volume":"13","author":"Schmitz","year":"2006","journal-title":"Gene Ther"},{"key":"10.1002\/ijc.29442-BIB0055|ijc29442-cit-0055","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00006676-200107000-00011","article-title":"Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death","volume":"23","author":"Ibrahim","year":"2001","journal-title":"Pancreas"},{"key":"10.1002\/ijc.29442-BIB0056|ijc29442-cit-0056","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1158\/1535-7163.MCT-06-0075","article-title":"Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells","volume":"5","author":"Khanbolooki","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1002\/ijc.29442-BIB0057|ijc29442-cit-0057","first-page":"407","article-title":"Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells","volume":"7","author":"Matsuzaki","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1002\/ijc.29442-BIB0058|ijc29442-cit-0058","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/onc.2012.164","article-title":"On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics","volume":"32","author":"Dimberg","year":"2013","journal-title":"Oncogene"},{"key":"10.1002\/ijc.29442-BIB0059|ijc29442-cit-0059","first-page":"2854","article-title":"Ex vivo infection of live tissue with oncolytic viruses","volume":"52","author":"Diallo","year":"2011","journal-title":"J Vis Exp"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.29442","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/ijc.29442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T16:29:18Z","timestamp":1625156958000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.29442"}},"subtitle":["Oncolytic adenoviruses for MSC delivery to pancreatic cancer"],"short-title":[],"issued":{"date-parts":[[2015,2,20]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8,15]]}},"URL":"https:\/\/doi.org\/10.1002\/ijc.29442","relation":{},"ISSN":["0020-7136"],"issn-type":[{"value":"0020-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2,20]]}}}